Breaking the Silence: Rethinking Lupus Diagnosis with AI and Omics

Lupus affects millions worldwide—yet many patients wait years for a diagnosis. Why? The disease is notoriously difficult to catch early. Its symptoms mimic other conditions, lab tests are often inconclusive, and seronegative cases fall through the cracks. At Tashkhīs, we believe patients deserve better answers, faster.

The Science Behind Our Platform

Our solution brings together three core elements:

1. Blood-based multi-omics data — including gene expression markers like IFI27, SIGLEC-1, and BAFF, all of which are validated in early lupus and overlap syndromes.

2. AI-powered interpretation — trained on complex immune signatures, our algorithms flag early immune dysregulation, even when ANA/dsDNA tests are negative.

3. Non-invasive workflow — a single blood sample can offer a molecular view of disease activity, flare risk, and even organ-specific involvement.

We’re not just building another diagnostic—we’re building a proactive, predictive platform that empowers clinicians and spares patients from diagnostic delay.

Built with Clinicians, For Clinicians

We are currently running pilot studies in partnership with leading hospitals, including patients with:

1. Overlapping autoimmune conditions (e.g., SLE + Sjögren’s, RA overlap)

2. Early-stage or undifferentiated autoimmune symptoms

3. Negative ANA but clinical manifestations of disease

This collaborative model ensures our platform reflects the complexity of real-world cases—not just textbook lupus.

Why This Matters

• Lupus is underdiagnosed: Patients with vague or non-specific symptoms are often dismissed or misdiagnosed.

• Delays cost lives: Organ damage can occur before autoantibodies ever show up.

• Conventional tests aren't enough: Our platform captures what routine labs miss—cellular immune signals, not just serology.

From Silence to Signal

Autoimmune diseases don't wait. Neither should diagnosis. At Tashkhīs, we’re combining cutting-edge science with a mission rooted in lived experience—to create tools that are smarter, faster, and finally empathetic to the complexity of autoimmunity.

If you’re a clinician, researcher, or health system partner who wants to bring this vision to life—we want to hear from you.